# FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer

> **NCT01439542** · PHASE2 · TERMINATED · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 19 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiation
- **DRUG:** Luteinizing Hormone Releasing Hormone (LHRH) Agonist

## Key facts

- **NCT ID:** NCT01439542
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-09
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Higher then expected Gr3 GU/GI toxicity
- **Last updated:** 2018-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01439542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01439542, "FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01439542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*